Gotowe bibliografie tematyczne / Inhaled corticosteriods

Gotowa bibliografia na temat „Inhaled corticosteriods”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 20 lutego 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Inhaled corticosteriods”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Inhaled corticosteriods"

1

SHI, Yali, i Wenjing ZHANG. "Medication analysis and treatment of a case of celostomia caused by inhaled corticosteriods". Pharmaceutical Care and Research 21, nr 1 (28.02.2021): 66–68. http://dx.doi.org/10.5428/pcar20210115.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

FISH, JAMES E, STEPHEN P PETERS, CHRISTOPHER V CHAMBERS, STEPHEN J McGEADY, KENNETH R EPSTEIN, HOMER A BOUSHEY, REUBEN M CHERNIACK i in. "An Evaluation of Colchicine as an Alternative to Inhaled Corticosteriods in Moderate Asthma". American Journal of Respiratory and Critical Care Medicine 156, nr 4 (październik 1997): 1165–71. http://dx.doi.org/10.1164/ajrccm.156.4.9703012.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Self, Timothy, Mark J. Rumbak, Tiffany Kelso, Louis Eberle, Nabil Abou-Shala, Cheryl C. Learned, Nicole Beiers i Elizabeth Tolley. "Does salmeterol facilitate “step-down” therapy in patients with asthma receiving moderate to high doses of inhaled corticosteriods?" Current Therapeutic Research 59, nr 11 (listopad 1998): 803–11. http://dx.doi.org/10.1016/s0011-393x(98)85106-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

THARWANI, ARSAL, HIMANSHU DESHWAL i JOSEPH PARAMBIL. "USE OF INHALED CORTICOSTERIODS/LONG-ACTING BETA AGONIST (ICS-LABA) IN PATIENTS WITH BRONCHIOLITIS CAUSED BY SJÖGREN SYNDROME DECREASES NEED FOR ORAL STEROIDS". Chest 162, nr 4 (październik 2022): A2193. http://dx.doi.org/10.1016/j.chest.2022.08.1812.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Wu, Ann Chen, Pamela M. McMahon, Emily Welch, Cheryl N. McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang i in. "Characteristics of new adult users of mepolizumab with asthma in the USA". BMJ Open Respiratory Research 8, nr 1 (listopad 2021): e001003. http://dx.doi.org/10.1136/bmjresp-2021-001003.

Pełny tekst źródła
Streszczenie:
BackgroundIn the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for patients aged ≥12 years with an eosinophilic phenotype.Objectives(1) Describe baseline demographic and clinical characteristics of new US adult mepolizumab users 2015–2019, (2) describe asthma medication use in the 12 months preceding initiation of and concomitant with mepolizumab and (3) assess mepolizumab adherence, persistence and discontinuation patterns in 12 months postinitiation.MethodsWe conducted a new-user observational cohort study using data from Aetna, a CVS Health Company, HealthCore (Anthem), Harvard Pilgrim Healthcare, and IBM MarketScan Research Databases. Curated administrative claims data in the FDA Sentinel System common data model format and publicly available Sentinel analytical tools were used to query the databases. We included adults who initiated mepolizumab in 2015–2019 with an asthma diagnosis in the preceding 12 months and no evidence of cystic fibrosis. We examined age, sex, comorbid conditions, asthma medication use and severe asthma exacerbations.ResultsWe identified 3496 adults (mean age 54.2 years, SD 12.5 years) who initiated mepolizumab. In the 12 months before mepolizumab initiation, 22% had received inhaled corticosteroids, 46% had inhaled corticosteroid/long-acting beta agonists, 72.6% had leukotriene antagonists, 38% had long-acting muscarinic antagonist, 18% had omalizumab,<1% had reslizumab, dupilumab or benralizumab. In the previous 12 months, 70% had a diagnosis of allergic rhinitis, 32% had chronic obstructive pulmonary disease, 17% eosinophilia and 3% eosinophilic granulomatosis with polyangiitis. Further, 56% had an asthma-related ambulatory visit, 73%≥1 course of oral corticosteroids lasting 3–27 days, 10% an asthma-related emergency department visit and 22% an asthma-related hospitalisation. In the 12 months following initiation, the mean proportion of days covered was 70%, and reductions in the average mean dispensings of rescue oral corticosteriods (35%) and omalizumab (61%) were observed.ConclusionsAdults with asthma treated with mepolizumab had varying levels of healthcare utilisation and we observed evidence of mepolizumab use in patients without severe asthma.
Style APA, Harvard, Vancouver, ISO itp.
6

Pizzichini, Marcia MM, Emilio Pizzichini, Krishnan Parameswaran, Lynda Clelland, Ann Efthimiadis, Jerry Dolovich i Frederick E. Hargreave. "Nonasthmatic Chronic Cough: No Effect of Treatment with an Inhaled Corticosteriod in Patients without Sputum Eosinophilia". Canadian Respiratory Journal 6, nr 4 (1999): 323–30. http://dx.doi.org/10.1155/1999/434901.

Pełny tekst źródła
Streszczenie:
BACKGROUND: Inhaled corticosteroids are effective in suppressing a chronic cough without asthma associated with sputum eosinophilia.OBJECTIVE: To investigate the inflammatory characteristics in the induced sputum of patients with a chronic cough without asthma or known cause and the effects of budesonide treatment on chronic cough in those patients.PATIENTS AND METHODS: Forty-four adults (mean [minimum, maximum] age of 45 years [20,75], 28 women, 17 atopic subjects and 32 nonsmokers]), with a daily bothersome cough for at least one year and who had no evidence of asthma or other known cause for the cough, were consecutively enrolled. The trial was a randomized, double-blind, controlled parallel group trial of budesonide 400 mg twice daily for two weeks versus placebo. Patients then received open administration of the same dose of budesonide for a further two weeks. Sputum was induced before and at the end of each treatment period. Cough severity was documented by a visual analogue scale.RESULTS: Thirty-nine (89%) patients produced mucoid sputum after induction on at least one study visit. At baseline, the majority (59%) had a mild elevation in the median proportion of neutrophils (65%). All had elevated fluid phase levels of fibrinogen (3200 µg/L) and albumin (880 µg/L), and high levels of interleukin-8 and substance P. Interleukin-8 correlated with neutrophils (rho=0.72, P<0.001), fibrinogen (rho=0.65, P<0.001), albumin (rho=0.67, P=0.001) and eosinophil cationic protein (rho=0.60, P=0.001). Substance P correlated with albumin (rho=0.60, P=0.006). No subject had an increase in eosino-phils. Treatment with budesonide did not affect cough or sputum measurements.CONCLUSIONS: Patients with nonasthmatic chronic cough enrolled in this study had evidence of a mild neutrophilia and/or microvascular leakage. Chronic cough did not respond to treatment with budesonide, perhaps because the cause was not associated with sputum eosinophilia.
Style APA, Harvard, Vancouver, ISO itp.
7

Reardon, G., i P. Navaratnam. "Risk Factors for Exacerbations in Pediatric Asthmatic Patients Receiving Montelukast Monotherapy (MON) Who Step Up to an Inhaled Corticosteriod (ICS) or a Fixed-Dose Combination of ICS and Long-Acting Beta Agonist (ICSLABA)". Journal of Allergy and Clinical Immunology 125, nr 2 (luty 2010): AB171. http://dx.doi.org/10.1016/j.jaci.2009.12.668.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

"META-ANALYSIS OF INHALED CORTICOSTERIODS AND SHORT TERM GROWTH IN ASTHMATIC CHILDREN". Paediatric Respiratory Reviews 7 (styczeń 2006): S264. http://dx.doi.org/10.1016/j.prrv.2006.05.006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Rozprawy doktorskie na temat "Inhaled corticosteriods"

1

Sothirajah, Shobana. "Clinical Algorithms for Maintaining Asthma Control". Thesis, The University of Sydney, 2008. http://hdl.handle.net/2123/3546.

Pełny tekst źródła
Streszczenie:
Rationale: Asthma management aims to achieve optimal control on the minimal effective dose of medication. We assessed the effectiveness of two algorithms to guide ICS dose in well-controlled patients on ICS+LABA in a double-blind study, comparing dose adjustment guided by exhaled nitric oxide (eNO) to clinical care algorithm(CCA) based on symptoms and lung function. Methods: We randomised non-smoking adult asthmatics on minimum FP dose 100μgs daily +LABA to ICS adjustment using eNO or CCA, assessed over 5 visits during 8 months treatment. Primary endpoints were asthma-free days and asthma related quality of life (QOL). Analysis was by mixed model regression and generalised estimating equations with log link. Results: 69 subjects were randomised (eNO:34, CCA:35) and 58 completed the study. At baseline mean FEV1 was 94% pred., mean eNO (200ml/sec) 7.1 ppb, median ACQ6 score 0.33. Median ICS dose was 500 μg (IQR 100-500) at baseline and 100 μg on both eNO (IQR 100-200) and CCA arms (IQR 100–100) at end of study. There were no significant differences between eNO and CCA groups in asthma-free days (RR=0.92, 95% CI 0.8–1.01), AQL (RRAQL
Style APA, Harvard, Vancouver, ISO itp.
2

Sothirajah, Shobana. "Clinical Algorithms for Maintaining Asthma Control". University of Sydney, 2008. http://hdl.handle.net/2123/3546.

Pełny tekst źródła
Streszczenie:
Master of Science in Medicine
Rationale: Asthma management aims to achieve optimal control on the minimal effective dose of medication. We assessed the effectiveness of two algorithms to guide ICS dose in well-controlled patients on ICS+LABA in a double-blind study, comparing dose adjustment guided by exhaled nitric oxide (eNO) to clinical care algorithm(CCA) based on symptoms and lung function. Methods: We randomised non-smoking adult asthmatics on minimum FP dose 100μgs daily +LABA to ICS adjustment using eNO or CCA, assessed over 5 visits during 8 months treatment. Primary endpoints were asthma-free days and asthma related quality of life (QOL). Analysis was by mixed model regression and generalised estimating equations with log link. Results: 69 subjects were randomised (eNO:34, CCA:35) and 58 completed the study. At baseline mean FEV1 was 94% pred., mean eNO (200ml/sec) 7.1 ppb, median ACQ6 score 0.33. Median ICS dose was 500 μg (IQR 100-500) at baseline and 100 μg on both eNO (IQR 100-200) and CCA arms (IQR 100–100) at end of study. There were no significant differences between eNO and CCA groups in asthma-free days (RR=0.92, 95% CI 0.8–1.01), AQL (RRAQL
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Inhaled corticosteriods"

1

Land, Cassia L., Jennifer Walker, Kevin Frick, Mona Tsoukleris i Arlene Butz. "Association Of Pharmacy Location With Fills Of Inhaled Corticosteriods (ICS) In Urban Children With Asthma". W American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3808.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii